CoChat

Engineered Nanoparticles for Drug Delivery in Cancer Therapy

Sun, Tianmeng, Zhang, Yu Shrike, Pang, Bo, Hyun, Dong Choon, Yang, Miaoxin, Xia, Younan · 2014 · Angewandte Chemie International Edition

The DOI matches its Crossref record; 579 of the 579 references it cites were found in a registry or an index.

Abstract

In medicine, nanotechnology has sparked a rapidly growing interest as it promises to solve a number of issues associated with conventional therapeutic agents, including their poor water solubility (at least, for most anticancer drugs), lack of targeting capability, nonspecific distribution, systemic toxicity, and low therapeutic index. Over the past several decades, remarkable progress has been made in the development and application of engineered nanoparticles to treat cancer more effectively. For example, therapeutic agents have been integrated with nanoparticles engineered with optimal sizes, shapes, and surface properties to increase their solubility, prolong their circulation half‐life, improve their biodistribution, and reduce their immunogenicity. Nanoparticles and their payloads have also been favorably delivered into tumors by taking advantage of the pathophysiological conditions, such as the enhanced permeability and retention effect, and the spatial variations in the pH value. Additionally, targeting ligands (e.g., small organic molecules, peptides, antibodies, and nucleic acids) have been added to the surface of nanoparticles to specifically target cancerous cells through selective binding to the receptors overexpressed on their surface. Furthermore, it has been demonstrated that multiple types of therapeutic drugs and/or diagnostic agents (e.g., contrast agents) could be delivered through the same carrier to enable combination therapy with a potential to overcome multidrug resistance, and real‐time readout on the treatment efficacy. It is anticipated that precisely engineered nanoparticles will emerge as the next‐generation platform for cancer therapy and many other biomedical applications.

Overview

Integrity signals

Registry

Crossref · 10.1002/anie.201403036

Cites

579 of 579 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 30

  1. Aruna U., 2013, Inter. J. Inn. Pharm. Res., 4, 318
  2. Langer R., 1998, Nature, 392, 5
  3. Petre C. E., 2007, Int. J. Nanomed., 2, 277
  4. Lao J., 2013, J. Drug Delivery, 456409
  5. Saif M. W., 2007, JOP, 8, 166
  6. Matsumura Y., 1986, Cancer Res., 46, 6387
  7. 10.1002/1097-0142(20011115)92:10<2592::AID-CNCR1612>3.0.CO;2-4 · doi:10.1002/1097-0142(20011115)92:10<2592::aid-cncr1612>3.0.co;2-4
  8. Xu G., 2001, Clin. Cancer Res., 7, 3314
  9. 10.1016/j.addr.2012.09.008 · doi:10.1016/j.addr.2012.09.008 · Paper page
  10. Pundir S., 2013, Int. J. Drug Res. Technol., 3, 12
  11. 10.1021/jp077468 · doi:10.1021/jp077468
  12. Mohanraj V. J., 2006, J. Pharm. Res., 5, 561
  13. Ma Y. D., 2011, Int. J. Nanomed., 6, 2679
  14. 10.1002/(SICI)1097-4636(199908)46:2<236::AID-JBM13>3.0.CO;2-F · doi:10.1002/(sici)1097-4636(199908)46:2<236::aid-jbm13>3.0.co;2-f
  15. Krishna R., 2000, Eur. J. Cancer Sci., 11, 265
  16. Kettiger H., 2013, Int. J. Nanomed., 8, 3255
  17. Yuan F., 1995, Cancer Res., 55, 3752
  18. Jain R. K., 1987, Cancer Res., 47, 3039
  19. 10.1021/nn900002m · DOI · Paper page
  20. Chidambaram M., 2012, Int. J. Pharm. Sci., 2, 117
  21. 10.1039/C1CS15237H · DOI · Paper page
  22. 10.1038/nnano.2007.223 · DOI · Paper page
  23. Mohanraj V. J., 2006, Trop. J. Pharm. Res., 5, 561
  24. Hong R. L., 1999, Clin. Cancer Res., 5, 3645
  25. Shamsipour F., 2009, Avicenna J. Med. Biotechnol., 1, 27
  26. Park J. W., 2002, Clin. Cancer Res., 8, 1172
  27. Uppada S. B., 2014, Int. J. Nanomed., 9, 43
  28. Bangham A. D., 1965, J. Mol. Biol., 13, 227
  29. Mueller C., 1994, Methods Cell Sci., 16, 183
  30. 10.1016/j.cbpa.2005.10.005 · DOI

Cited by

See all 2,164

Metadata

Authors
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y.
Affiliations
Georgia Institute of Technology (US)
Venue
Angewandte Chemie International Edition
Publisher
Wiley
Published
2014-10-07
Volume
53
Issue
46
Pages
12320-12364
ISSN
  • 1433-7851 (ISSN-L)
  • 1521-3773
OpenAlex
W2134726513
Cited by
2,164
References
578
Citations by year
2026: 57 · 2025: 146 · 2024: 163 · 2023: 153 · 2022: 209 · 2021: 200 · 2020: 221 · 2019: 237 · 2018: 257 · 2017: 230 · 2016: 180 · 2015: 109 · 2014: 2
FWCI
11.84
Type
journal article
Language
en
Open access
closed
Locations
  • Angewandte Chemie International Edition (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
Keywords
engineered nanoparticles, drug delivery, cancer therapy, targeted drug delivery, enhanced permeability and retention effect, pH-responsive delivery, tumor-targeting ligands, tissue distribution, circulation half-life, immunogenicity, combination therapy, multidrug resistance, contrast media, theranostics, nanoparticle surface modification
MeSH terms
Animals, Antineoplastic Agents, Delayed-Action Preparations, Humans, Neoplasms, Drug Delivery Systems, Nanotechnology, Nanomedicine, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.